about
Chronic hepatitis C virus infection and lipoprotein metabolismCD36 genetic variation, fat intake and liver fibrosis in chronic hepatitis C virus infectionCapitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine designInvolvement of MAP3K8 and miR-17-5p in poor virologic response to interferon-based combination therapy for chronic hepatitis C.The effect of the severity of liver cirrhosis on the level of lipids and lipoproteinsElevated miR-33a and miR-224 in steatotic chronic hepatitis C liver biopsiesUp-regulation of the ATP-binding cassette transporter A1 inhibits hepatitis C virus infection.Farnesyl-diphosphate farnesyltransferase 1 regulates hepatitis C virus propagation.Lipid profile in cirrhotic patients and its relation to clinical outcomeHigh level of serum cholesteryl ester transfer protein in active hepatitis C virus infection.Immunologic, metabolic and genetic factors in hepatitis C virus infection.The acyclic retinoid Peretinoin inhibits hepatitis C virus replication and infectious virus release in vitro.Small heterodimer partner 1 directly interacts with NS5A viral protein and has a key role in HCV related liver cell transformation.Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment.Association of lipid droplet and hepatitis C virus proteins: insights for virus replication.Lipid testing in infectious diseases: possible role in diagnosis and prognosis.Metabolic syndrome: an ill wind that blows some good?Prevalence of pruritus in patients with chronic liver disease: a multicenter study.Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9.Changes in serum lipid profiles caused by three regimens of interferon-free direct-acting antivirals for patients infected with hepatitis C virus.Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin.Genotype specific peripheral lipid profile changes with hepatitis C therapy.Apolipoprotein E-ε4 deficiency and cognitive function in hepatitis C virus-infected patients.Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection.LIPID PROFILE OF CIRRHOTIC PATIENTS AND ITS ASSOCIATION WITH PROGNOSTIC SCORES: a cross-sectional study.Assessment of the features of serum apolipoprotein profiles in chronic HCV infection: difference between HCV genotypes 1b and 2.Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.Analysis of Hepatitis C Virus Particle Heterogeneity in Immunodeficient Human Liver Chimeric fah-/- Mice.Plasma triglyceride levels may modulate hepatitis C viral replication.A new role for IKK-α in hepatitis C virus-induced lipogenesis.Long Non-coding RNAs in Hepatitis C Virus-Infected Cells.Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b.In vivo analysis at the cellular level reveals similar steatosis induction in both hepatitis C virus genotype 1 and 3 infections.Hidden heterogeneity in Alzheimer's disease: Insights from genetic association studies and other analyses.Newly discovered hepatitis C virus minicores circulate in human blood.Regulation of the Interferon Response by lncRNAs in HCV Infection.Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy
P2860
Q26784234-DE02096F-57E6-4388-AFE2-FA82136D10E6Q27468740-DBC84768-A1FD-478D-9508-9A9F0D480775Q30374314-F42EDCA9-C557-4101-B0D7-F2C28DDBC555Q33599325-09955CAE-8B8C-4D33-B97C-4D58F6E47EF9Q34422605-76393B78-4960-4893-8C76-7C472A201268Q34467266-A9865DF3-E7EF-4459-B8DE-DFF58053B0B0Q35125004-C8F6A14D-182E-40EA-9CBD-1D9227919267Q35137045-9B36DFFF-2749-4052-BA8F-4FF067E46174Q36533249-5D693EB4-2CF6-4BE8-AE11-0AC38D398EA1Q36590937-A9DEC127-9C6A-4D20-916E-E5E747185997Q37682496-CB9C8B40-3B14-4FF7-9F16-7E834D03EA87Q37702746-C946326B-A433-4C61-8ACE-BAF49417499AQ37708986-8AE368ED-BB12-4B38-B2F0-4250F5A0D15BQ37718004-DAA1B442-EA65-4A4B-9FAB-9826379C6FE2Q39214596-D8983053-1BE4-44C2-B645-732562E468B0Q39293001-D65B4E15-0FB3-4BA2-8220-F4CC64726500Q39882865-06F15A7A-8B79-474F-BFBB-07A76061C9C8Q40055616-D52222F8-2778-4F98-A9C9-38CA9CCD69EDQ40061048-D58376DA-9EF7-434D-B3BE-C3B1DD0B851CQ40073683-84DA9ED5-CB25-4026-94B5-A5BD6F37A5DEQ40167729-F20673AB-6B05-496E-BA74-4B2E756A7F56Q40393590-43FEA42F-19DE-44FB-A8BB-825637BBBE5CQ40607877-B2560893-3873-4FCA-BF39-EFFBA6DD8540Q40659995-D23764FD-C837-42BB-BABE-EC9AD903C892Q40943348-78FD4A41-AD03-4F3C-B5DB-1F0A17440581Q41094437-4D9A76D3-0832-471B-9F61-93CD5F308860Q41564973-F70F3468-AB4B-4E0D-99E7-B08799D16156Q41705191-F58240B2-9E0D-4D0E-8800-2B8E08B9071FQ42235591-FB3FFA69-870A-49CF-96BC-3193449D91ADQ42244326-EFF8083F-0239-437F-8558-3C6A71D2452FQ42369135-24FFD75D-90CD-470B-9E5E-3E990B8B894EQ43136598-DFBDBA08-CC22-44FA-86B2-15A3A4BB91F9Q45323722-FEBFD172-C0C9-4492-A44E-9F6991A7F3CDQ45325483-98B1EB4B-664A-4828-92FD-CB49B48AC076Q47625969-C5ADAD4D-2D1C-45A1-B12F-64C15552CE95Q52699061-DA11840F-4CB8-4AF3-893A-C1E08172B6CEQ55122208-7178116C-E879-4F39-8DD9-B8110472183EQ58785077-93EEB7D1-A77B-4022-93C6-642E771FF0A8
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Lipids and HCV.
@en
type
label
Lipids and HCV.
@en
prefLabel
Lipids and HCV.
@en
P2860
P50
P1476
Lipids and HCV
@en
P2093
M F Bassendine
R D G Neely
P2860
P2888
P304
P356
10.1007/S00281-012-0356-2
P577
2012-10-31T00:00:00Z
P5875
P6179
1048029910